NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









X-tosis, Inc.

X-tosis, Inc.

Private
Gainesville, FloridaEnterprise Softwarehttps://www.x-tosis.com/

Last Round

Grant

Jun 23, 2026

Total Funding Raised

$2.74M

Momentum

Top 1%

of companies Caplight tracks

Company Overview

X-tosis, Inc. is a biotechnology company that develops first-in-class mitochondrial therapeutics targeting VDAC1 oligomerization to treat neurodegenerative diseases such as Alzheimer's and Parkinson's.

Sector

Enterprise Software

Verticals

Biotechnology, Drug Discovery, Vertical SaaS

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

biotechnologydrug discoverymitochondrial therapeuticsprecision medicinebiotechneurodegenerative diseasepreclinical developmentresearch and developmentR&Dbiotech startuptherapeutic developmentdata managementresearch reproducibilitycustom GPTAI assistant

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

X-tosis, Inc. Comparables

Compare X-tosis, Inc. with similar companies based on industry and business-model similarity.

X-tosis, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Capacity Bio
44%
ScandiBio Therapeutics
42%
MitoSense, Inc.
34%

X-tosis, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJun 23, 2026

Key People

Founding team and executive leadership

Yotam Nisemblat

Founder & Chief Scientific Officer

Founding Team

X-tosis, Inc. Investors

Notable investors and investment history

X-tosis, Inc. investors
InvestorRounds
The Michael J. Fox Foundation for Parkinson's ResearchGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 23, 2026

    Received $2.74M from The Michael J. Fox Foundation

X-tosis, Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

X-tosis, Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about X-tosis, Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersGainesville, Florida
Employee Range5
Year Founded2024
Last FundingJun 23, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.